QC
HZNP

QCM Cayman’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

QCM Cayman’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,874
Closed -$192K – 458
2016
Q4 		$192K Buy
+11,874
New +$215K 0.38% 90
2016
Q3 		– Sell
-25,502
Closed -$420K – 388
2016
Q2 		$420K Buy
+25,502
New +$413K 0.18% 80

Other funds holding HZNP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

QCM Cayman's HZNP Position: Q1 2017 in Review

QCM Cayman sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2017, closing a stake of 11,874 shares — an estimated $192K sold.

QCM Cayman first reported a position in HZNP in Q2 2016 and held it in 2 quarters. The position peaked at $420K in Q2 2016. 210 funds tracked by Wall St. Rank hold HZNP as of Q1 2017.

  • QCM Cayman reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2017 after selling out during the quarter.
  • QCM Cayman sold 11,874 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2017, an estimated $192K.
  • QCM Cayman first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 2 quarters.
  • QCM Cayman's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $420K in Q2 2016.
  • 210 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2017.

Based on QCM Cayman's 13F filing for Q1 2017, filed 15 May 2017.